Screening of the entire ryanodine receptor type 1 coding region for sequence variants associated with malignant hyperthermia susceptibility in the North American population

Anesthesiology

Volumn 102, Issue 3, 2005, Pages 515-521

  Sambuughin, Nyamkhishig ^b   Holley, Heather ^c   Muldoon, Sheila ^d   Brandom, Barbara W ^e   De Bantel, Astrid M ^a   Tobin, Joseph R ^g   Nelson, Tom E ^f   Goldfarb, Lev G ^b  

^a MD Student Training Program   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c BARROW NEUROLOGICAL INSTITUTE   (United States)

^d UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^e CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

RYANODINE RECEPTOR; RYANODINE RECEPTOR 1; UNCLASSIFIED DRUG;

CLUSTER ANALYSIS; CODING; CONFERENCE PAPER; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; GENE LOCATION; GENETIC HETEROGENEITY; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; HYPERTHERMIA; MALIGNANT HYPERTHERMIA; NONHUMAN; NORTH AMERICA; NUCLEOTIDE SEQUENCE; PERIPHERAL LYMPHOCYTE; POPULATION RESEARCH; PRIORITY JOURNAL; RECEPTOR GENE; RELIABILITY; SCREENING; SEQUENCE ANALYSIS;

ANIMALS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALIGNANT HYPERTHERMIA; MUTATION; OPEN READING FRAMES; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL;

EID: 14644397272     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-200503000-00007     Document Type: Conference Paper

References (36)

1. Hopkins PM: Malignant hyperthermia: Advances in clinical management and diagnosis. Br J Anesth 2000; 85:118-28
2. Larach MG: Standardization of the caffeine halothane muscle contracture test. North American Malignant Hyperthermia Group. Anesth Analg 1989; 69: 511-5
3. Jurkat-Rott K, McCarthy T, Lenmann-Horn F: Genetics and pathogenesis of malignant hyperthermia. Muscle Nerve 2000; 23:4-17
4. Robinson RL, Curran JL, Ellis FR, Halsall PJ, Hall WJ, Hopkins PM, Iles DE, West SP, Shaw MA: Multiple interacting gene products may influence susceptibility to malignant hyperthermia. Ann Hum Genet 2000; 64:307-20
5. McCarthy TV, Quane KA, Lynch PJ: Ryanodine receptor mutations in malignant hyperthermia and central core disease. Hum Mut 2000; 15:410-7
6. Phillips MS, Fujii J, Khanna VK, DeLeon S, Yokobata K, De Jong PJ, MacLennan DH: The structural organization of the human skeletal muscle ryanodine receptor (RYR1) gene. Genomics 1996; 34:24-41
7. Mickelson JR, Ross JA, Hyslop RJ, Gallant EM, Louis CF: Skeletal muscle sarcolemma in malignant hyperthermia: Evidence for a defect in calcium regulation. Biochim Biophys Acta 1987; 897:364-76
8. Gillard EF, Otsu K, Fujii J, Duff C, DeLeon S, Khanna, Britt BA, Worton RG, and MacLennan DH: Polymorphisms and deduced amino acid substitutions in the coding sequence of the ryanodine receptor (RYR1) gene in individuals with malignant hyperthermia. Genomics 1992; 13:1247-54
9. Robinson R, Curran JL, Hall WJ, Halsall PJ, Hopkins PM, Markham AF, Stewart AD, West SP, Ellis FR: Genetic heterogeneity and HOMOG analysis in British malignant hyperthermia families. J Med Genet 1998; 35:196-201
10. Brandt A, Schleithoff L, Jurkat-Rott K, Klingler W, Baur C, and Lehmann-Horn F: Screening of the ryanodine receptor gene in 105 malignant hyperthermia families: Novel mutations and concordance with the in vitro contracture test. Hum Mol Genet 1999; 8:2055-62
11. Sambuughin N, Sei Y, Gallagher KL, Wyre HW, Madsen D, Nelson TE, Fletcher JE, Rosenberg H, Muldoon SM: North American malignant hyperthermia population: Screening of the ryanodine receptor gene and identification of novel mutations. ANESTHESIOLOGY 2001; 95:594-9
12. Ruffert H, Olthoff D, Duetrich C, Meinecke CD, Froster UG: Mutation screening in the ryanodine receptor gene (RYR1) in patients susceptible to malignant hyperthermia who show definite IVCT results: Identification of three novel mutations. Acta Anaesthesiol Scand 2002; 46:692-8
13. Monnier N, Romero NB, Lerale J, Landrieu P, Nivoche Y, Fardeau M, Lunardi J: Familial and sporadic forms of central core disease are associated with mutations in the C-terminal domain of the skeletal muscle ryanodine receptor. Hum Mol Genet 2001; 10:2581-92
14. Tilgen N, Zorzato F, Halliger-Keller B, Muntoni F, Sewry C, Palmucci LM, Schneider C, Hauser E, Lehmann-Horn F, Muller CR, Treves S: Identification of four novel mutations in the C-terminal membrane spanning domain of the ryanodine receptor 1: Association with central core disease and alteration of calcium homeostasis. Hum Mol Genet 2001; 10:2879-87
15. ++ regulating proteins. Curr Mol Medicine 2002; 2:347-69
16. Galli L, Orrico A, Cozzolino S, Pietrini V, Tegazzin V, Sorrentino V: Mutations in the RYR1 gene in Italian patients at risk for malignant hyperthermia: Evidence for a cluster of novel mutations in the C-terminal region. Cell Calcium 2002; 32:143-51
17. Davis MR, Haan E, Jungbluth H, Sewry C, North K, Muntoni F, Kuntzer T, Lament P, Bankier A, Tomlinson P, Sanchez A, Walsh P, Nagarajan L, Oley C, Colley A, Gedeon A, Quinlivan R, Dixon J, James D, Muller CR, Laing NG: Principal mutation hotspot for central core disease and related myopathies in the C-terminal transmembrane region of the RYR1 gene. Neuromuscul Disord 2003; 13:151-7
18. Bennett RR, Dunnen J, O'Brien KF, Darras BT, Kunkel LM: Detection of mutations in the dystrophin gene via automated DHPLC screening and direct sequencing. BMC Genetics 2001; 2:1471-2156
19. Bagattin A, Veronese C, Bauce B, Wuyts W, Settimo L, Nava A, Rampazzo A, Danieli GA: Denaturing HPLC-based approach for detecting RYR2 mutations involved in malignant arrhythmias. Clin Genet 2004; 50:1148-55
20. Brown RL, Pollock AN, Couchman KG, Hodges M, Hutchinson DO, Rupene W, Lynch P, McCarthy TV, Stowell KM: A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree. Hum. Mol. Genet 2000; 9:1515-24
21. Jungbluth H, Muller CR, Halliger-Keller B, Brockington M, Brown SC, Feng L, Chattopadhyay A, Mercuri E, Manzur AY, Ferreiro A, Liang NG, Davis MR, Roper HP, Dubowitz V, Bydder G, Sewry CA, Muntoni F: Autosomal recessive inheritance of RYR1 mutations in a congenital myopathy with cores. Neurology 2002; 59:284-7
22. Wadhwa RK: Obstetric anesthesia for a patient with malignant hyperthermia susceptibility. ANESTHESIOLOGY 1977; 46:63-4
23. Xiao W, Oefner PJ: Denaturing high-performance liquid chromatography: A review. Hum Mut 2001; 17:439-74
24. Ito T, Takeshima Y, Yagi M, Kamei S, Wada H, Nakamura H, Matsuo M: Analysis of dystrophin mRNA from skeletal muscle but not from lymphocytes led to identification of a novel nonsense mutation in a carrier of Duchenne muscular dystrophy. J Neurol 2003; 250:581-7
25. Ravnik-Glavac M, Atkinson A, Glavac D, Dean M: DHPLC screening of cystic fibrosis gene mutations. Hum Mutat 2002; 19:374-83
26. Ferreiro A, Monnier N, Romero NB, Leroy JP, Bonnemann C, Haenggeli CA, Straub V, Voss WD, Nivoche Y, Jungbluth H, Lemainque A, Voit T, Lunarid J, Fardeau M, Guicheney P: A recessive form of central core disease, transiently presenting as multi-minicore disease, is associated with a homozygous mutation in the Ryanodine Receptor type 1 gene. Ann Neurol 2002; 51:750-9
27. Robinson RL, Anetseder MJ, Brancadoro V, Broekhoven C, Carsana A, Censier K, Fortunato G, Girard T, Heytens L, Hopkins PM, Jurkat-Rott K, Klinger W, Kozak-Ribbens G, Krivosic R, Monnier N, Olthoff D, Rueffert H, Sorrentino V, Tegazzin V, Mueller CR: Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing? Eur J Hum Genet 2003; 11:342-8
28. Girard T, Treves S, Voronkov E, Siegemund M, Urwyler A: Molecular genetic testing for malignant hyperthermia susceptibility. ANESTHESIOLOGY 2004; 100:1076-80
29. Sambuughin N, McWilliams S, de Bantel A, Sivakumar K, Nelson TE: Single-amino-acid deletion in the RYR1 gene associated with malignant hyperthermia susceptibility and unusual contraction phenotype. Am J Hum Genet 2001; 69:204-8
30. Sambuughin N, Nelson TE, Jankovic J, Xin C, Meissner G, Mullakandov M, Ji J, Rosenberg H, Sivakumar K, Goldfarb L: Identification and functional characterization of a novel ryanodine receptor mutation causing malignant hyperthermia in North American and South American families. Neuromuscul Disord 2001; 11:530-7
31. Wehner M, Rueffert H, Koenig F, Olthoff D: Functional characterization of malignant hyperthermia-associated RyR1 mutations in exon 44, using the human myotube model. Neuromuscul Disord 2004; 14:429-37
32. Scacheri PC, Hoffman EP, Fratkin JD, Semino-Mora C, Senchak A, Davis MR, Laing NG, Vedanarayanan V, Subramony SH: A novel ryanodine receptor gene mutation causing both cores and rods in congenital myopathy. Neurology 2000; 55:1689-96
33. Davis M, Brown R, Dickson A, Horton H, James D, Laing N, Marston R, Norgate M, Perlman D, Pollock N, Stowell K: Malignant hyperthermia associated with exercise-induced rhabdomyolysis or congenital abnormalities and a novel RYR1 mutation in New Zealand and Australian pedigrees. Br J Anaesth 2002; 88:508-15
34. Tammaro A, Bracco A, Cozzolino S, Esposito M, Di Martino A, Savoia G, Zeuli L, Piluso G, Aurino S, Nigro V: Scanning for mutations of the ryanodine receptor (RYR1) gene by denaturing HPLC: Detection of three novel malignant hyperthermia alleles. Clin Chem 2003; 49:761-8
35. Loke JC, Kraev N, Sharma P, Du G, Patel L, Kraev A, MacLennan DH: Detection of a novel ryanodine receptor subtype 1 mutation (R328W) in a malignant hyperthermia family by sequencing of a leukocyte transcript. ANESTHESIOLOGY 2003; 99:297-302
36. Sei Y, Sambuughin N, Davis EJ, Sachs D, Cuenca P, Brandom BW, Tautz T, Rosenberg H, Nelson TE, Muldoon SM: Malignant hyperthermia in North America: Screening the three hotspots in the type I ryanodine receptor gene. ANESTHESIOLOGY 2004; 101:824-30